These authors contributed equally.
Article first published online: 22 APR 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 53, Issue 5, pages 1538–1548, May 2011
How to Cite
Yoo, B. K., Santhekadur, P. K., Gredler, R., Chen, D., Emdad, L., Bhutia, S., Pannell, L., Fisher, P. B. and Sarkar, D. (2011), Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology, 53: 1538–1548. doi: 10.1002/hep.24216
Potential conflict of interest: Nothing to report.
D.S. is the Harrison Endowed Scholar in Cancer Research and Blick scholar. P.B.F. holds the Thelma Newmeyer Corman Chair in Cancer Research and is a Samuel Waxman Cancer Research Foundation (SWCRF) Investigator.
- Issue published online: 22 APR 2011
- Article first published online: 22 APR 2011
- Accepted manuscript online: 10 FEB 2011 11:31AM EST
- Manuscript Accepted: 21 JAN 2011
- Manuscript Received: 12 OCT 2010
- James S. McDonnell Foundation and the Dana Foundation and National Cancer Institute. Grant Number: R01 CA138540-01A1
- National Institutes of Health. Grant Number: R01 CA134721
There is virtually no effective treatment for advanced hepatocellular carcinoma (HCC) and novel targets need to be identified to develop effective treatment. We recently documented that the oncogene Astrocyte elevated gene-1 (AEG-1) plays a seminal role in hepatocarcinogenesis. Employing yeast two-hybrid assay and coimmunoprecipitation followed by mass spectrometry, we identified staphylococcal nuclease domain containing 1 (SND1), a nuclease in the RNA-induced silencing complex (RISC) facilitating RNAi-mediated gene silencing, as an AEG-1 interacting protein. Coimmunoprecipitation and colocalization studies confirmed that AEG-1 is also a component of RISC and both AEG-1 and SND1 are required for optimum RISC activity facilitating small interfering RNA (siRNA) and micro RNA (miRNA)-mediated silencing of luciferase reporter gene. In 109 human HCC samples SND1 was overexpressed in ≈74% cases compared to normal liver. Correspondingly, significantly higher RISC activity was observed in human HCC cells compared to immortal normal hepatocytes. Increased RISC activity, conferred by AEG-1 or SND1, resulted in increased degradation of tumor suppressor messenger RNAs (mRNAs) that are target of oncomiRs. Inhibition of enzymatic activity of SND1 significantly inhibited proliferation of human HCC cells. As a corollary, stable overexpression of SND1 augmented and siRNA-mediated inhibition of SND1 abrogated growth of human HCC cells in vitro and in vivo, thus revealing a potential role of SND1 in hepatocarcinogenesis. Conclusion: We unravel a novel mechanism that overexpression of AEG-1 and SND1 leading to increased RISC activity might contribute to hepatocarcinogenesis. Targeted inhibition of SND1 enzymatic activity might be developed as an effective therapy for HCC. (HEPATOLOGY 2011;)
Astrocyte elevated gene-1 (AEG-1), also known as metadherin (MTDH), lyric and 3D3, plays an important role in regulating carcinogenesis.1 Analysis of a large group of patient cohorts and cancer cell lines has established that AEG-1 is overexpressed in a diverse array of cancers, including hepatocellular carcinoma (HCC), and there is an inverse statistical correlation between AEG-1 expression level versus poor prognosis and reduced patient survival.1 In all of the cancer indications studied, overexpression of AEG-1 confers a highly aggressive, angiogenic, and metastatic phenotype, whereas small interfering RNA (siRNA) inhibition reverses these phenotypes in nude mice xenograft models.1 AEG-1 activates multiple protumorigenic signaling pathways, profoundly modulates global gene expression patterns that contribute to invasion, metastasis, and chemoresistance, and promotes transformation and angiogenesis.1-4 However, how exactly AEG-1 induces all these events still remains to be elucidated.
Staphylococcal nuclease domain containing 1 (SND1), also known as p100 coactivator or Tudor-SN, is a multifunctional protein modulating transcription, messenger RNA (mRNA)-splicing, RNA interference (RNAi) function, and mRNA stability.5-10 In the cytoplasm, SND1 functions as a nuclease in the RNA-induced silencing complex (RISC) in which small RNAs (such as siRNAs or micro RNA [miRNAs]) are complexed with ribonucleoproteins to ensure RNAi-mediated gene silencing.10 Little information is available on the role of SND1 in tumorigenesis. Antisense inhibition of SND1 in B lymphoblasts results in cell death, indicating that SND1 is required for cell survival.11 Proteomic profiling identified high SND1 expression in metastatic breast cancer cells and also in tumor samples of metastatic breast cancer patients.12 A recent study shows that SND1 is one of the highly overexpressed genes in human colon cancers, both in patient samples and in cell lines.13 Overexpression of SND1 in rat intestinal epithelial cells resulted in loss of contact inhibition and promoted cell proliferation.13 As yet, there are no reports of SND1 involvement in HCC.
In the present study we identify SND1 as an AEG-1 interacting protein in RISC facilitating RISC activity. Inhibition of SND1 abrogates oncogenic functions of AEG-1, and SND1 expression itself is increased in human HCC. Overexpression and inhibition studies revealed the importance of SND1 in mediating hepatocarcinogenesis. These findings reveal a novel interplay between RISC components in promoting hepatocarcinogenesis.
Materials and Methods
Cell Lines, Culture Condition, Viability, and Clonogenic Assays.
HepG3, QGY-7703, Hep3B, and Huh7 human HCC cells and human embryonic kidney 293 (HEK293) cells were cultured as described.2 Generation of Hep-AEG-1-14 clone, HepG3 cells stably expressing AEG-1, and Hep-pc-4, HepG3 cells stably transduced with empty pcDNA3.1 vector, has been described.2 HepG3 cells were transfected with control or AEG-1 siRNA expression plasmid and individual clones were selected for 2 weeks in 250 μg/mL hygromycin. QGY-7703 cells were transduced with a pool of three to five lentiviral vector plasmids, each encoding target-specific 19-25 nucleotides (nt) (plus hairpin) SND1 short hairpin RNA (shRNA) (Santa Cruz Biotechnology) and were selected for 2 weeks in 1 μg/mL puromycin. Hep3B cells were transfected with SND1-Myc-FLAG expression construct and the individual clones were selected in 800 μg/mL G418 for 2 weeks. Cell viability was determined by standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays as described.2 3′,5′-Deoxythymidine bisphosphate (pdTp) was used at a dose of 50, 100, and 200 μM.10 For colony formation assay, cells (500) were plated in 6-cm dishes and colonies >50 cells were counted after 2 weeks.
Tissue Microarray and Immunostaining.
Human HCC tissue microarrays were obtained from Imgenex. Two tissue microarrays were used: one containing 40 primary HCC, 10 metastatic HCC, and 9 normal adjacent liver samples (Imgenex; IMH-360), the other containing 46 primary HCC and 13 metastatic HCC (Imgenex; IMH-318). Immunostaining was performed using anti-SND1 antibody (rabbit polyclonal; 1:100; Prestige Antibodies Powered by Atlas Antibodies from Sigma) that has been validated by immunohistochemistry against hundreds of normal and diseased tissues as described.2
Coimmunoprecipitation and Western Blot Analyses.
Cells were harvested in 1× cell lysis buffer (Cell Signaling) containing protease and phosphatase inhibitor cocktails (Roche). Cell lysates were precleared by incubation with protein A agarose for 1 hour at 4°C. The agarose beads were removed by centrifugation and the supernatant was incubated with the primary antibody overnight at 4°C. The antigen-antibody conjugates were incubated with protein A agarose for 2 hours at 4°C and washed four times with 1× cell lysis buffer. Agarose beads were suspended in 1× sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer, boiled, and then subjected to western blot analyses.
Nude Mice Xenograft Studies.
Subcutaneous xenografts were established in the flanks of athymic nude mice using 1 × 106 different clones of HCC cells. Tumor volume was measured twice weekly with a caliper and calculated using the formula π/6 × larger diameter × (smaller diameter)2. All experiments were performed with at least five mice in each group and all the experiments were repeated three times.
Data are represented as the mean ± standard error of mean (SEM) and analyzed for statistical significance using one-way analysis of variance (ANOVA) followed by Newman-Keuls test as a post-hoc test. P < 0.05 was considered significant.
AEG-1 Interacts with SND1.
To identify AEG-1-interacting proteins we first employed yeast two-hybrid (Y2H) screening. We used as baits the N-terminal (amino acid [a.a.] 1-57) and C-terminal (a.a. 68-582) regions of AEG-1 that precedes and follows the transmembrane domain, respectively, to separately screen a human liver complementary DNA (cDNA) library using the technology of Hybrigenics (http://www.hybrigenics-services.com). The C-terminal region showed autoactivator function, thereby complicating the assay. However, using selective medium containing 20 mM of 3-aminotriazole (3-AT), the inhibitor of the reporter gene product, the assay could be optimized. Despite these efforts only five known proteins with moderate confidence in the interaction were identified (Supporting Information Table S1). One of these proteins was SND1.
The relatively modest result of the Y2H screening prompted us to employ an alternative strategy of coimmunoprecipitation coupled with mass spectrometry. We have already established stable clones of HepG3 cells expressing HA-tagged AEG-1 (Hep-AEG-1-14).2 Cell lysates from Hep-AEG-1-14 and Hep-pc-4 cells (control hygromycin-resistant clone of HepG3 cells) were subjected to immunoprecipitation using protein A agarose conjugated with anti-HA antibody (anti-HA agarose). The immunoprecipitates were eluted using HA peptide and were run in an SDS-PAGE gel (Supporting Information Fig. S1). The gel was stained with Coommassie blue and the stained bands, which were present only in Hep-AEG-1-14 immunoprecipitates but not in Hep-pc-4 immunoprecipitates, were cut and were subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis after in-gel trypsin digestion. A total of 182 potential AEG-1-interacting proteins were thus identified. However, the most represented proteins were AEG-1 and SND1 (#33 and #174 in Supporting Information Table S2, respectively).
The interaction between SND1 and AEG-1 was confirmed by coimmunoprecipitation analysis using lysates from QGY-7703 human HCC cell that expresses abundant AEG-1 and SND1. Anti-SND1 antibody pulled down AEG-1 and vice versa, demonstrating the interaction (Fig. 1A). To confirm these findings we transfected an HA-tagged AEG-1 expression construct and an FLAG-Myc-tagged SND1 expression construct into HEK-293 cells and performed coimmunoprecipitation analysis. Anti-HA antibody pulled down FLAG-tagged SND1, whereas anti-FLAG antibody pulled down HA-tagged AEG-1, thus documenting the interaction (Fig. 1B). To determine in which intracellular compartment AEG-1 and SND1 interact, double immunofluorescence analysis was performed. QGY-7703 cells were stained with chicken anti-AEG-1 antibody and Alexa Fluor 546-conjugated antichicken secondary antibody and with rabbit anti-SND1 antibody and Alexa Fluor 488-conjugated antirabbit secondary antibody. The images were analyzed using a confocal Laser scanning microscope. The colocalization of AEG-1 and SND1 was determined by yellow staining in the merged image. AEG-1 and SND1 were detected predominantly in the cytoplasm, although a low level of punctate staining for both was also detected in the nucleus (Fig. 1C, Supporting Information Fig. S2). However, the colocalization of AEG-1 and SND1 was observed only in the cytoplasm and not in the nucleus (Fig. 1C, Supporting Information Fig. S2). Cytoplasmic colocalization of AEG-1 and SND1 was also observed when human HCC sections were analyzed in a similar method (Supporting Information Fig. S3A). HEK-293 cells were transfected with AEG-1-HA and SND1-FLAG-Myc constructs and double immunofluorescence analysis using anti-HA and anti-FLAG antibodies also detected cytoplasmic colocalization of AEG-1 and SND1 (Supporting Information Fig. S3B).
To check which region of AEG-1 interacts with SND1, HEK-293 cells were transfected with a series of N-terminal and C-terminal deletion mutants of AEG-1, all with HA-tag, and an FLAG-Myc-tagged SND1 expression construct (Fig. 2A).14 Immunoprecipitation was performed with anti-Myc antibody and immunoblotting was performed with anti-HA antibody. SND1 interacted with all the C-terminal deletion mutants of AEG-1, the smallest containing a.a. 1-289 (Fig. 2A). Deletion of the first 101 a.a. residues of AEG-1 maintained AEG-1/SND1 interaction. However, deletion to a.a. 205 residues prevented the interaction (Fig. 2A). Thus, a.a. 101-205 residues of AEG-1 interact with SND1.
AEG-1 Is a Component of RISC.
Cytoplasmic SND1 has been shown to function as the nuclease in RISC.10 To check whether AEG-1 is also a component of RISC, we analyzed the interaction between AEG-1 and another major component of RISC, Ago2,15 by coimmunoprecipitation analysis using lysates from QGY-7703 cells. Anti-AEG-1 antibody pulled down Ago2 and vice versa, demonstrating the interaction (Fig. 2B, Fig. 2C). To confirm these findings further, we transfected HEK-293 cells with an Myc-tagged Ago2 expression construct and with either an empty pcDNA3.1 vector or an HA-tagged AEG-1 expression construct. Immunoprecipitation with anti-HA antibody followed by immunoblotting with anti-Myc antibody detected a band representative of Ago2 only in AEG-1-transfected cells but not in pcDNA3.1-transfected cells (Fig. 2D). Similarly, immunoprecipitation with anti-Myc antibody followed by immunoblotting with anti-HA antibody detected a band representative of AEG-1 only in AEG-1-transfected cells but not in pcDNA3.1-transfected cells (Fig. 2D), thereby documenting that AEG-1 and Ago2 reside in the same complex. Double immunofluorescence studies demonstrated colocalization of Ago2 and AEG-1 (Fig. 2E) as well as that of Ago2 and SND1 (Supporting Information Fig. S4). To check the potential contribution of these proteins in the formation of RISC, AEG-1 and Ago2 interaction was analyzed in QGY-SND1si-12 clone (QGY-7703 cells with stable knockdown of SND1). SND1 knockdown resulted in significant reduction in AEG-1 and Ago2 interaction as observed by coimmunoprecipitation analysis (Fig. 3A,B). Knocking down AEG-1 in HepG3 cells did not interfere with SND1 and Ago2 interaction (Fig. 3C,D), indicating that SND1 might be the key molecule in RISC formation.
We next tested the impact of AEG-1 on RISC activity using a Renilla luciferase (Rluc) reporter gene bearing in its 3′ untranslated region (UTR) one target of a microRNA (miRNA23) (Fig. 4A, Supporting Information Fig. S5) as previously done to evidence the miRNA-dependent RISC activity in cell cultures.16 Plasmid pRLTK and pRLTK 1x (containing the miRNA23-target) were transfected into Hep-pc-4 and Hep-AEG-1-14 cells together with a plasmid expressing the Firefly luciferase gene (Fluc) for normalization. We used short duplex RNAs (sdRNAs) that have been demonstrated to work as miRNAs or siRNAs, depending on their complementarity with the target. We tested both perfect (sdRNA P) and imperfect/bulged (sdRNA B) sdRNAs to mimic the siRNA or the miRNA pathways, respectively. In Hep-pc-4 and Hep-AEG-1-14 cells, when no target was present on the reporter gene (pRLTK) or when a nonspecific sdRNA (sdRNA C) was used along with pRLTK 1x, no effect was observed (Fig. 4C). In the case of pRLTK 1x, a specific inhibition in Rluc activity (indicative of increased RISC activity) was observed in Hep-pc-4 cells with 10 nM sdRNA P (Fig. 4C). However, this inhibition was significantly more pronounced in Hep-AEG-1-14 cells. The inhibition of Rluc activity was also observed for sdRNA B, although at a much lower efficiency than that of sdRNA P. There was a statistically significant increased inhibition of Rluc activity by sdRNA B in Hep-AEG-1-14 cells compared to Hep-pc-4 cells (Fig. 4C). These findings were confirmed using HepG3 cells stably expressing either control, scrambled siRNA (Hep-Consi), or AEG-1 siRNA (Hep-AEG-1si) (Fig. 4D). The RISC activity (inhibition of Rluc activity) was significantly less in Hep-AEG-1si cells compared to Hep-Consi cells for both sdRNA P and B, although the effect for sdRNA B was less pronounced compared to that for sdRNA P. Similar findings were observed using malignant glioma cells T98G stably expressing AEG-1 siRNA (Supporting Information Fig. S5). These findings demonstrate that as a component of RISC, AEG-1 contributes to its functional activity. We also document that Hep3B human HCC cells stably overexpressing SND1 demonstrate higher RISC activity compared to the control cells, whereas QGY-7703 cells stably expressing SND1 siRNA exhibits lower RISC activity compared to their control counterparts (Fig. 4E,F, respectively). The expression of AEG-1 and SND1 in the knockdown and overexpressing clones is shown in Fig. 4B.
Inhibition of enzymatic activity of SND1 by pdTp as well as knockdown of Ago2 by siRNA significantly inhibited RISC activity in QGY-7703 cells (Supporting Information Fig. S6). However, the effect of Ago2 siRNA was significantly more than that of pdTp in inhibiting RISC activity, indicating that although SND1 contributes to optimum RISC activity, Ago2 is the more important nuclease in conferring RISC function.
Because AEG-1 expression is markedly higher in HCC compared to normal liver, we tested whether RISC activity is higher in human HCC cells compared to THLE-3 cells that are normal human hepatocytes immortalized by SV40 T/t Ag. Indeed, RISC activity was significantly lower in THLE-3 cells (38% decrease in Rluc activity) compared to Hep3B, QGY-7703, and Huh7 cells (59%, 63%, and 73% decrease in Rluc activity), respectively (Fig. 5A). We hypothesized that increased RISC activity might contribute to hepatocarcinogenesis by augmenting oncomiR-mediated degradation of tumor suppressor mRNAs. Accordingly, we selected several mRNAs that are regulated by miRNAs overexpressed in HCC. These mRNAs include PTEN, target of miR-221 and miR-21; CDKN1C (p57), target of miR-221; CDKN1A (p21), target of miR-106b; SPRY2, target of miR-21, and TGFBR2, target of miR-93.17, 18 Indeed, we observed that overexpression of AEG-1 or SND1 down-regulates, whereas knockdown of AEG-1 or SND1 up-regulates, all these mRNA levels in HCC cells, thus supporting our hypothesis (Fig. 5B,C).
SND1 Inhibition Abrogates AEG-1 Function.
We next checked the importance of AEG-1/SND1 interaction, and therefore RISC activity, in mediating AEG-1 function by inhibiting enzymatic activity of SND1. pdTp, a specific competitive inhibitor of staphylococcal nucleases, inhibits SND1 at 100 μM concentration.10 Hep-pc-4 and Hep-AEG-1-14 cells were treated with pdTp at 50, 100, and 200 μM concentrations and cell viability was measured by standard MTT assay. Both the cell lines showed significant growth inhibition upon pdTp treatment (Fig. 6A). However, Hep-pc-4 cells showed more sensitivity to pdTp compared to Hep-AEG-1-14 cells. On day 4, there was 46% and 32% reduction in cell viability in Hep-pc-4 and Hep-AEG-1-14 cells, respectively, upon treatment with 200 μM pdTp. The colony formation ability of Hep-pc-4, Hep-AEG-1-14, Hep3B, and QGY-7703 cells were analyzed next. The expression level of both AEG-1 and SND1 is higher in QGY-7703 cells compared to Hep3B cells (Fig. 4B). The clonogenic activity was significantly inhibited by pdTp treatment by 46%, 30%, 55%, and 43% in Hep-pc-4, Hep-AEG-1-14, Hep3B, and QGY-7703 cells, respectively (Fig. 6B). These findings indicate that inhibition of RISC activity inhibits cell growth and overexpression of AEG-1 can partially protect from this effect. Transient transfection of SND1 siRNA also resulted in significant inhibition of anchorage-independent growth in soft agar in Hep-AEG-1-14 and QGY-7703 cells (Supporting Information Fig. S7). However, SND1 inhibition (either by pdTp or by siRNA) did not affect increased Matrigel invasion activity conferred by AEG-1 (data not shown), indicating that SND1 primarily plays a role in regulating cell growth and proliferation.
SND1 Is Overexpressed in HCC.
The observation that inhibition of SND1 can significantly inhibit cell growth and viability prompted us to probe deeper into SND1 involvement in HCC. At first we examined the SND1 expression pattern by immunohistochemistry in tissue microarrays containing 86 primary HCC, 23 metastatic HCC, and 9 normal adjacent liver samples. SND1 expression was detected predominantly in the cytoplasm (Fig. 6C). None of the normal liver and HCC samples stained negative for SND1 (Fig. 6C, Table 1). However, compared to normal liver there was a significant increase in SND1 expression in 81 out of 109 HCC patients (≈74%). SND1 expression gradually increased with the stages of the disease based on the Barcelona Liver Clinic Cancer (BCLC) staging system that showed significant statistical correlation (Table 1).
|Intensity of SND1 staining|
|Stage I HCC||0||11||12||0||23|
|Stage II HCC||0||9||16||0||25|
|Stage III HCC||0||7||23||8||38|
|Stage IV HCC||0||1||7||15||23|
SND1 Promotes Tumorigenesis by Human HCC Cells.
We next checked the consequence of stable overexpression of SND1 in Hep3B and stable knockdown of SND1 in QGY-7703 human HCCs in the contexts of cell growth and tumorigenicity. Compared to the control neomycin-resistant cells (Hep3B-Con), Hep3B-SND1-17 clones had significant augmentation in cell growth and proliferation as observed by standard MTT and colony-forming assays (Fig. 7A,B, respectively). On the contrary, the QGY-SND1si-12 clone showed significantly slower cell growth and proliferation compared to QGY-Consi clone stably expressing control scrambled siRNA (Fig. 7A,B). In the in vivo nude mice xenograft assay, the Hep3B-SND1-17 clone formed significantly larger subcutaneous tumors compared to the Hep3B-Con clone (Fig. 7C-E). As a corollary, the QGY-Consi clone formed significantly larger tumor compared to the QGY-SND1si-12 clone (Fig. 7C-E). Similar findings were observed in additional SND1-overexpressing clones of Hep3B cells and SND1-knockdown clones of QGY-7703 cells (Supporting Information Fig. S8).
Nuclear SND1 functions as a transcriptional coactivator and helps in pre-mRNA splicing and AEG-1 also modulates transcription.6, 7, 14, 19 However, we did not detect colocalization of AEG-1 and SND1 in the nucleus and we documented that AEG-1 interacts with SND1 in the cytoplasm, facilitating RISC activity. Cells lacking fragile X mental retardation protein, another component of RISC, have normal RISC activity,16 further supporting the contribution of AEG-1 in maintaining optimum RISC function. More important, we demonstrate that both AEG-1 and SND1 are overexpressed in HCC compared to normal liver, and human HCC cells exhibit higher RISC activity compared to normal immortal hepatocytes. We hypothesized that augmented RISC activity might lead to enhanced degradation of tumor suppressor mRNAs by oncomiRs, and indeed we document that knocking down AEG-1 or SND1 increases, whereas overexpression of AEG-1 or SND1 decreases the level of several tumor suppressor mRNAs, targets of miRNAs that are overexpressed in HCC (Fig. 5B,C). What might be the role of AEG-1 in RISC? The lack of any enzymatic domain indicates that AEG-1 might be a scaffold protein favoring formation of complex multiprotein structures such as RISC.
We identified that the region of AEG-1 protein containing a.a. 101-205 interacts with SND1. Interestingly, the same region also interacts with p65 subunit of nuclear factor kappaB (NF-κB) and a.a. 72-169 interacts with another AEG-1 interacting protein, BCCIPα.14, 20 Bioinformatic analysis could not identify any known potential protein/protein interaction domain or motif in this region of AEG-1, indicating that this region might be a unique and novel protein/protein interaction domain. Mutational analysis of this region will help identify which amino acid residues of AEG-1 are critical for mediating these interactions and thus might be potential hot spots that might be targeted by small molecules to inhibit AEG-1 function.
Apart from a few isolated studies, little is known about the role of SND1 in tumorigenesis. As such, we were surprised to find the relatively high expression of SND1 in human HCC samples compared to normal liver. Indeed, we observed that overexpression of SND1 in Hep3B cells, expressing a low level of SND1, augments, whereas inhibition of SND1 in QGY-7703 cells, expressing a high level of SND1, abrogates in vitro viability and in vivo tumorigenicity in nude mice. We also observed that inhibition of enzymatic (nuclease) activity of SND1 by the chemical inhibitor pdTp decreases viability of human HCC cells, indicating that functional SND1, or functional RISC activity, is required for maintaining cell viability. Our findings are supported by a recent study demonstrating that SND1 is cleaved by caspases during drug-induced apoptosis.21 A noncleavable SND1 mutant increased cell viability and knocking down SND1 promoted drug-induced apoptosis in HeLa cells.21 Incubation with caspases completely blocked RNase activity of SND1, indicating that SND1 enzymatic activity is required for maintaining cell viability or protection from apoptosis.
Hepatocellular carcinoma is one of the top five malignancies worldwide.22 The advanced disease is highly resistant to standard radio- and chemotherapy and virtually no effective treatment is available even for palliative treatment. Identification of novel targets thus facilitates development of new modalities of effective treatment for this fatal disease. Screening for small molecule inhibitors of SND1 enzymatic activity with a clinically achievable dose might usher in an effective therapeutic regimen not only for HCC but also for other SND1-overexpressing tumors.
Additional Supporting Information may be found in the online version of this article.
|HEP_24216_sm_suppinfofig1.tif||1155K||Supporting Information Figure 1|
|HEP_24216_sm_suppinfofig2.tif||4333K||Supporting Information Figure 2|
|HEP_24216_sm_suppinfofig3.tif||2671K||Supporting Information Figure 3|
|HEP_24216_sm_suppinfofig4.tif||1877K||Supporting Information Figure 4|
|HEP_24216_sm_suppinfofig5.tif||8874K||Supporting Information Figure 5|
|HEP_24216_sm_suppinfofig6.tif||1370K||Supporting Information Figure 6|
|HEP_24216_sm_suppinfofig7.tif||750K||Supporting Information Figure 7|
|HEP_24216_sm_suppinfofig8.tif||2431K||Supporting Information Figure 8|
|HEP_24216_sm_suppinfotbl1.xls||45K||Supporting Information Table 1|
|HEP_24216_sm_suppinfotbl2.xls||47K||Supporting Information Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.